2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4491 Cost-of-illness among patients with hematological malignancies in a post-conflict setting: A preliminary analysis from Syria

Ayla Kouli, MD, Ahmad Al-Bitar, MD2, Luna AlMardini, MD3, Miriam Laflouf, MD4, Jaafar Mustafa5, Hazem Al Zabadany, MD6, Ameen Suliman, MD7, Monzr M. M Al Malki, MD8
1 Damascus University, Damascus, Syria, Arab Rep., Mayo Clinc, Phoenix, Arizona, United States
2 Damascus University, Damascus, Syria, Arab Rep.
3 Syrian private university, Damascus, Syria, Arab Rep.
4 Damascus University, Damascus, Syria, Arab Rep.
5 Damascus University, Damascus, Syria, Arab Rep.
6 Damascus University, Damascus, Syria, Arab Rep.
7 Damascus University, Damascus, Syria, Arab Rep.
8 City of Hope, Duarte, United States

Background: Hematological malignancies impose substantial economic burden on patients and their families, particularly in low-resource and post-conflict settings where healthcare financing structures are fragmented and out-of-pocket expenditure predominates. Data quantifying the direct medical, direct non-medical, and indirect costs borne by these patients, and their downstream effect on treatment adherence, remain limited in this context. This study aims to evaluate financial toxicity associated with hematological malignancy diagnosis and treatment in Syria which potentially affects disease outcomes.


Methods: A cross-sectional, cost-of-illness study is being conducted among patients with confirmed hematological malignancies receiving care in Syrian healthcare facilities. Data are collected via structured interviews capturing sociodemographic characteristics, clinical and treatment profiles, direct medical costs (hospital visits, medications, laboratory tests, procedures), direct non-medical costs (transportation, accommodation), indirect costs (work cessation, lost productivity), and self-reported coping strategies (borrowing, asset liquidation). Catastrophic health expenditure (CHE) was defined as out-of-pocket spending exceeding 50% of monthly household income. Associations were assessed using Mann-Whitney U, Chi-square, Kruskal-Wallis, and Spearman correlation tests; independent predictors of treatment delay and CHE were evaluated using binary logistic regression. This report presents interim findings from the first 42 enrolled patients; enrollment and data collection are continuing.


Results: Among 42 patients analyzed to date (mean age 46.0 ± 18.3 years; 54.8% male), leukemia (47.6%) and lymphoma (35.7%) were the predominant diagnoses, and 69.0% received chemotherapy-based regimens. Total treatment costs over the preceding three months frequently exceeded 8–15 million SYP (~600-1200$ ), with 14.3% of patients reporting costs above 40 million SYP (~3100$). A majority of patients (59.5%) spent more than 75% of monthly household income on care, and 97.6% rated the financial burden as high or catastrophic. Distress financing was common: 88.1% of patients borrowed money and 66.7% sold assets to fund treatment. Half of the cohort (50.0%) reported postponing or discontinuing treatment due to inability to pay. Lower household income was independently associated with asset liquidation (Mann-Whitney U = 84.5, p = 0.004) and with CHE (OR = 0.55, 95% CI 0.35–0.87, p = 0.011). Borrowing money independently predicted treatment delay (OR = 4.82, 95% CI 1.42–16.35, p = 0.012) in multivariate logistic regression (model χ² (3) = 16.42, p < 0.001; Nagelkerke R² = 0.44). Proportion of income spent on care correlated positively with self-reported disruption of family basic needs (r? = 0.68, p < 0.001). Procedural costs did not differ significantly by cancer diagnosis (H(2) = 1.85, p = 0.397).


Conclusion: Preliminary findings indicate that patients with hematological malignancies in this post-conflict setting encounter substantial direct and indirect costs relative to household income, with a high prevalence of catastrophic expenditure and distress-financing behaviors.

 

Ayla Kouli, MD: No relevant conflicts of interest to declare.